POSITIVE RESULTS FROM PILOT FIELD EFFECTIVENESS STUDY OF KIND-016
We plan to begin a pivotal study on IL 31 by year-end 2020
“Itch associated with Atopic Dermatitis may be caused by either neurogenic, inflammatory and/or behavioral pathomechanisms. I often find that I need to address a combination of pathways to successfully control itch in my atopic patients.”
- Tony Yu, BSc, DVM, MS ACVD
KindredBio is pursuing a multi-pronged approach toward atopic dermatitis, with a portfolio of promising biologics.
KindredBio reported positive topline results from its pilot field effectiveness study of KIND-016, a fully caninized, high-affinity monoclonal antibody targeting interleukin-31, for the treatment of atopic dermatitis in dogs.
The company also expects pilot effectiveness results for its canine anti-IL-4/IL-13 SINK molecule by the first quarter of 2020 and is advancing other programs for atopic dermatitis.
Itch is #1 reason for canine veterinarian visits
have atopic dermatitis, an allergic skin disease
Key Profit Center
of dogs seen by dermatologists suffer from from pruritis (itch)
increase in itchy dog veterinarian vists since 2014
Current market size is $600M annually and growing.